Innoviva Inc.

6 days ago · defenseworld.net

Innoviva (NASDAQ: INVA - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 99.1% of Innoviva

8 days ago · defenseworld.net

Baird Financial Group Inc. acquired a new stake in Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 274,391 shares of the biotechnology company's stock, valued at approximately $6,231,000. Baird Financial Group Inc. owned 0.38%

2 months ago · seekingalpha.com

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.

2 months ago · zacks.com

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.

2 months ago · defenseworld.net

Dimensional Fund Advisors LP grew its holdings in shares of Innoviva, Inc. (NASDAQ: INVA) by 1.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,436,427 shares of the biotechnology company's stock after acquiring an additional 76,026 shares during the period. Dimensional Fund Advisors LP owned

3 months ago · businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact.

4 months ago · seekingalpha.com

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4 months ago · gurufocus.com

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica

4 months ago · fool.com

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

5 months ago · zacks.com

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.